Dalazatide (TFA)

• UNSPSC Description:

  Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease[1][2][3].

• Target Antigen:

  Potassium Channel

• Type:

  Peptides

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/dalazatide-tfa.html

• Purity:

  99.17

• Solubility:

  DMSO : ≥ 100 mg/mL|H2O : 100 mg/mL (ultrasonic)

• Smiles:

  CC[C@H](C)[C@@H]1NC([C@H](CSSC[C@H](NC([C@@H](NC(CNC(C2CSSC[C@@H]3NC([C@H](CCC(N)=O)NC([C@H](Cc4ccccc4)NC([C@H](C)NC([C@@H](NC([C@H](CSSC[C@H](NC([C@H](Cc5ccccc5)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](Cc6ccc(O)cc6)NC([C@H](CCCCN)NC([C@H](CCSC)NC([C@H](CO)NC([C@H](Cc7c[nH]cn7)NC([C@H](CCCCN)NC3=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C(NC(CCCNC(N)=N)C(NC(CCCCN)C(N[C@@H]([C@@H](C)O)C(N2)=O)=O)=O)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CO)NC([C@H](CCCCN)NC([C@@H]8CCCN8C([C@@H](NC([C@@H](NC([C@H](CC(O)=O)NC1=O)=O)[C@@H](C)O)=O)[C@@H](C)CC)=O)=O)=O)=O)=O)=O)[C@@H](C)O)=O)=O)=O)=O)=O)=O)[C@@H](C)O)=O)C(N)=O)NC([C@H](CO)NC([C@@](N(C(C)=O)C([C@@H](N)Cc9ccc(OP(O)(O)=O)cc9)=O)(CCCNC(N)=N)OCCOCCN)=O)=O)=O.OC(C(F)(F)F)=O.[x]

• Molecular Weight:

  4442.10 (free acid)

• References & Citations:

  [1]Olsen C, et al. Dalazatide (ShK-186), a first-in-class peptide inhibitor of Kv1. 3 potassium channels, demonstrates safety, tolerability and proof of concept of efficacy in patients with active plaque psoriasis. J. Invest. Dermatol., 2016, 136(8).|[2]Stevens A M, et al. Thu0285 Dalazatide, an Inhibitor of the KV1. 3 Channel on Activated Effector Memory T Cells, Has Immunotherapy Potential in Systemic Lupus Erythematosus. 2016.|[3]Matheu MP, et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 2008 Oct 17;29(4):602-14.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Clinical Information:

  Phase 1